Results
Following the sequence of our analyses, we first report results of our costing study. Second, we present the cost-effectiveness results of the base-case analysis using the data from the trial. Third, we report results of one-way sensitivity analyses on the four most influential parameters driving our cost-effectiveness estimates: extended implementation period to 12 months and 60 months; varying response rate from 20 to 50%; increasing prevalence from 0,4% to 1% and 4%; and setting the sensitivity of the pre-screening tool at 90%. Last, we report PSA results on cost per sample tested and cost per case detected.